uniQure CEO Matthew Kapusta Purchases 62,581 Shares

Matthew Kapusta, the CEO and Managing Director of uniQure N.V. (NASDAQ:QURE), made a significant purchase of the company's stock. On June 17, 2026, Kapusta bought 62,581 shares at an average price of $19.39 per share, totaling approximately $1.21 million. This transaction was not part of a pre-arranged trading plan.

What Changed in Matthew Kapusta's uniQure Position

Kapusta's recent purchase adds to his holdings in uniQure, a move that reflects his confidence in the company's future. The transaction, valued at over $1.21 million, was executed at a price of $19.39 per share, although the stock was trading near $46.37 on the following Monday.

Other Institutional Activity in uniQure

Several institutional investors have also adjusted their positions in uniQure. AVORO Capital Advisors LLC trimmed its holdings by 190,405 shares, bringing its total to 5,959,595 shares valued at approximately $97.4 million, a 3.1% decrease. In contrast, Aberdeen Group PLC increased its stake by 1,627,746 shares, resulting in a 44.2% increase to 5,306,386 shares worth about $86.8 million. Two Sigma Investments, LP significantly boosted its position by 1,224,587 shares, marking an 84.4% increase to 2,675,871 shares valued at $43.8 million. Meanwhile, RTW Investments, LP reduced its stake by 1,125,106 shares, a 30.3% decrease, ending with 2,586,356 shares valued at $42.3 million.

uniQure N.V. Stock Down 6.1%

Shares of NasdaqGS:QURE traded near $46.37 on Monday. uniQure has a market capitalization of roughly $2.92 billion. The stock has experienced a 52-week range between $8.73 and $71.50. Its 50-day moving average is $24.13, while the 200-day moving average is $27.53. The company's current ratio stands at 10.40, and its quick ratio is 9.97, with a debt-to-equity ratio of 365.37.

Recent Earnings

uniQure reported revenue of approximately $18.1 million, with a modest revenue growth rate of 1.27%. However, the company is not currently profitable, posting a net margin of 0.0% and a return on equity of -228.24%. The next earnings report is scheduled for July 29, 2026.

Insider Buying and Selling at uniQure N.V.

In addition to Kapusta's purchase, he also sold 41,671 shares at $50.00 per share on June 18, 2026, as part of a planned transaction. On the same day, he bought 4,656 shares at $31.71 per share. Another insider, Madhavan Balachandran, sold 11,685 shares at $45.06 per share on June 17, 2026, under a planned transaction.

Analysts Set New Price Targets

On June 18, 2026, Barclays upgraded uniQure to a 'buy' rating with a price target of $65. Goldman Sachs maintained a 'hold' rating, setting a target of $46. Leerink Partners and RBC Capital both maintained 'buy' ratings, with targets of $70 and $65, respectively. The consensus among analysts is a strong buy, with an average price target of approximately $58.75 based on 11 opinions.

About uniQure

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing treatments for rare and severe diseases. Its notable products include HEMGENIX for hemophilia B and AMT-130 for Huntington's disease. The company is also advancing several other gene therapy candidates in clinical trials. Founded in 1998, uniQure is led by CEO Matthew Kapusta and employs around 221 people.

Bottom Line

Matthew Kapusta's recent purchase of uniQure shares signals a strong belief in the company's growth potential. As a biotechnology firm, uniQure is engaged in cutting-edge treatments for rare diseases, which could drive future success. Investors should note that insider transactions, like Kapusta's, are reported after the fact and may not reflect current positions.